Santen Pharmaceutical Co., Ltd. Stock price

Equities

4536

JP3336000009

Pharmaceuticals

Market Closed - Japan Exchange 02:00:00 2024-03-28 am EDT 5-day change 1st Jan Change
1,486 JPY -0.23% Intraday chart for Santen Pharmaceutical Co., Ltd. +2.09% +5.80%
Sales 2024 * 301B 1.99B Sales 2025 * 292B 1.93B Capitalization 547B 3.62B
Net income 2024 * 31.42B 208M Net income 2025 * 33.39B 221M EV / Sales 2024 * 1.85 x
Net Debt 2024 * 10.05B 66.41M Net cash position 2025 * 13.82B 91.3M EV / Sales 2025 * 1.82 x
P/E ratio 2024 *
17.7 x
P/E ratio 2025 *
16.5 x
Employees 4,144
Yield 2024 *
2.17%
Yield 2025 *
2.31%
Free-Float 94.9%
More Fundamentals * Assessed data
Dynamic Chart
Santen Pharmaceutical to Cancel 12 Million Treasury Shares MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023. CI
Santen Pharmaceutical Co., Ltd.'s Equity Buyback announced on May 11, 2023, has closed with 12,571,400 shares, representing 3.38% for ¥16,178.35 million. CI
Santen Pharmaceutical's Returns to the Black in Fiscal Nine Months MT
Santen Pharmaceutical Co., Ltd. Revises Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,700 Yen From 1,650 Yen, Keeps at Buy MT
Santen Pharmaceutical Further Repurchases Shares for Over 1 Billion Yen MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023. CI
Santen Pharmaceutical Buys Back Nearly 2 Billion Yen of Shares MT
Santen Pharmaceutical’s Fiscal H1 EPS Increases to 69.68 Yen as Net Sales Rise 13.1% to 145.81 Billion Yen; Declares Interim Dividend of 16 Yen Per Share, Maintains Forecast MT
Santen Pharmaceutical Co., Ltd. Revises Consolidated Earnings Forecasts for the Fiscal Year Ending March 31, 2024 CI
Santen Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ended September 30, 2023, Payable on November 30, 2023; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2024 CI
Santen Pharmaceutical Buys Back 523,400 shares for 772.6 Million Yen in September MT
Tranche Update on Santen Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on May 11, 2023. CI
Jefferies Adjusts Santen Pharmaceutical’s Price Target to 1,650 Yen From 1,400 Yen, Keeps at Buy MT
More news
1 day-0.23%
1 week+2.09%
1 month-1.52%
3 months+6.10%
6 months+7.37%
Current year+5.80%
More quotes
1 week
1 455.00
Extreme 1455
1 518.00
1 month
1 416.50
Extreme 1416.5
1 523.50
Current year
1 397.50
Extreme 1397.5
1 589.50
1 year
1 060.00
Extreme 1060
1 589.50
3 years
956.00
Extreme 956
1 718.00
5 years
956.00
Extreme 956
2 234.00
10 years
897.00
Extreme 897
2 234.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 64 82-03-31
Director of Finance/CFO - -
Chairman 71 77-03-31
Members of the board TitleAgeSince
Chairman 71 77-03-31
Director/Board Member 63 15-05-31
Director/Board Member 67 22-06-23
More insiders
Date Price Change Volume
24-03-28 1,486 -0.23% 1 591 300
24-03-27 1,507 +1.34% 1,640,500
24-03-26 1,487 +0.30% 1,392,100
24-03-25 1,482 +0.47% 1,409,200
24-03-22 1,476 +1.34% 1,125,900

Delayed Quote Japan Exchange, March 28, 2024 at 02:00 am EDT

More quotes
SANTEN PHARMACEUTICAL CO., LTD. is a Japan-based pharmaceutical company engaged in the research, development, manufacturing and sales of pharmaceutical products. The Company has medical pharmaceutical business, OTC drugs business, medical devices business and other businesses. The Company engages in manufacture, sale and clinical development of medical pharmaceutical products, the development, manufacturing and sales of medical equipment, as well as the cleaning business. The Company operates in Japan, Europe, Asia, North America markets.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
1,507 JPY
Average target price
1,767 JPY
Spread / Average Target
+17.25%
Consensus
  1. Stock
  2. Equities
  3. Stock Santen Pharmaceutical Co., Ltd. - Japan Exchange